Danaher (NYSE:DHR) Given New $300.00 Price Target at Raymond James

Danaher (NYSE:DHR) had its price objective cut by Raymond James from $310.00 to $300.00 in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have an outperform rating on the conglomerate’s stock.

DHR has been the topic of several other research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price target on shares of Danaher in a research report on Friday, September 6th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Evercore ISI boosted their price target on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Leerink Partners raised their price objective on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Finally, The Goldman Sachs Group boosted their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $287.28.

Danaher Trading Down 2.0 %

NYSE:DHR opened at $256.00 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher has a one year low of $182.09 and a one year high of $281.70. The business’s 50-day simple moving average is $270.43 and its 200 day simple moving average is $260.43. The stock has a market cap of $189.62 billion, a price-to-earnings ratio of 43.39, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.02 earnings per share. As a group, sell-side analysts predict that Danaher will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.42%. Danaher’s payout ratio is currently 18.31%.

Insider Transactions at Danaher

In related news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 30,059 shares of company stock worth $8,400,897. Company insiders own 11.10% of the company’s stock.

Hedge Funds Weigh In On Danaher

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Danaher by 3.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 79,222 shares of the conglomerate’s stock worth $21,821,000 after buying an additional 2,879 shares in the last quarter. Parcion Private Wealth LLC grew its holdings in Danaher by 5.3% during the third quarter. Parcion Private Wealth LLC now owns 32,261 shares of the conglomerate’s stock worth $8,969,000 after acquiring an additional 1,615 shares during the period. Allworth Financial LP raised its position in Danaher by 6.1% in the third quarter. Allworth Financial LP now owns 5,337 shares of the conglomerate’s stock worth $1,484,000 after acquiring an additional 307 shares in the last quarter. Mayfair Advisory Group LLC acquired a new stake in Danaher in the 3rd quarter valued at about $203,000. Finally, Trueblood Wealth Management LLC boosted its holdings in Danaher by 2.5% during the third quarter. Trueblood Wealth Management LLC now owns 3,382 shares of the conglomerate’s stock worth $940,000 after buying an additional 84 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.